---
title: "Azitra, Inc. (AZTR.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/AZTR.US.md"
symbol: "AZTR.US"
name: "Azitra, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T12:44:02.754Z"
locales:
  - [en](https://longbridge.com/en/quote/AZTR.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/AZTR.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/AZTR.US.md)
---

# Azitra, Inc. (AZTR.US)

## Company Overview

Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S. epidermidis, which is in a Phase 1b/2a clinical trial for treating Netherton syndrome, a skin disease; and ATR-01, a genetically modified strain of S.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [azitrainc.com](https://azitrainc.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: E
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:15.000Z

**Overall: E (0.81)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 0 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: E

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% |  |
| Net Profit YoY | -29.78% |  |
| P/B Ratio | 0.29 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 3076563.22 |  |
| Revenue | 0.00 |  |

#### Multi Score Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -215.04% | E |
| Profit Margin | 0.00% | D |
| Gross Margin | 0.00% | E |
| Revenue YoY | -100.00% | E |
| Net Profit YoY | -23.11% | D |
| Total Assets YoY | -56.02% | E |
| Net Assets YoY | -71.72% | E |
| Cash Flow Margin | 0.00% | D |
| OCF YoY | -100.00% | E |
| Turnover | 0.00 | E |
| Gearing Ratio | 47.00% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Azitra, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-29.78%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.29",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "3076563.22",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "0.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-215.04%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-100.00%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-23.11%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-56.02%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-71.72%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-100.00%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "47.00%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.26 | 100/386 | - | - | - |
| PB | 0.29 | 14/386 | 1.34 | 1.02 | 0.86 |
| PS (TTM) | 365.43 | - | 423.77 | 365.43 | 365.43 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-13T04:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Overweight | 1 | 50% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.19 |
| Highest Target | 1.70 |
| Lowest Target | 1.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/AZTR.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/AZTR.US/norm.md)
- [Related News](https://longbridge.com/en/quote/AZTR.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/AZTR.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**